Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short term Debt: 2011-2025

Historic Short term Debt for Ani Pharmaceuticals (ANIP) over the last 9 years, with Sep 2025 value amounting to $15.2 million.

  • Ani Pharmaceuticals' Short term Debt rose 113.10% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year increase of 113.10%. This contributed to the annual value of $9.2 million for FY2024, which is 25.22% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Short term Debt of $15.2 million as of Q3 2025, which was up 15.32% from $13.2 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Short term Debt registered a high of $25.0 million during Q2 2023, and its lowest value of $850,000 during Q4 2021.
  • Its 3-year average for Short term Debt is $12.9 million, with a median of $12.3 million in 2023.
  • Per our database at Business Quant, Ani Pharmaceuticals' Short term Debt surged by 2,844.12% in 2023 and then tumbled by 96.60% in 2024.
  • Ani Pharmaceuticals' Short term Debt (Quarterly) stood at $850,000 in 2021, then remained steady at $850,000 in 2022, then soared by 1,343.06% to $12.3 million in 2023, then decreased by 25.22% to $9.2 million in 2024, then surged by 113.10% to $15.2 million in 2025.
  • Its last three reported values are $15.2 million in Q3 2025, $13.2 million for Q2 2025, and $11.2 million during Q1 2025.